Search results
Results From The WOW.Com Content Network
Draft laws, regulations and rules and policy plans on the administration and supervision of food (including food additives and health food, the same below) safety, drugs (including traditional Chinese medicines and ethno-medicines, the same below), medical devices and cosmetics; formulate normative documents, and facilitate the establishment and implementation of the food safety responsibility ...
It is estimated that the epidemic control measures held the death toll due to COVID-19 in Wuhan to under 5,000 from January to March 2020. [18] China was one of a small number of countries that pursued an elimination strategy, sustaining zero or low case numbers over the long term. [17]
During the COVID-19 pandemic, drug repurposing is the clinical research process of rapidly screening and defining the safety and efficacy of existing drugs already approved for other diseases to be used for people with COVID-19 infection.
While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks. By contrast, the BIBP vaccine can be transported and stored at normal refrigeration temperatures. [17]
Although not statistically significant, among these vaccinated participants, there was a reduction in the risk of COVID‑19 related hospitalization or death from any cause. [14] In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID ...
CNN, for example, published a report about the imposition of new restrictions and central government vetting, quoting an anonymous Chinese researcher's belief that the crackdown "is a coordinated effort from [the] Chinese government to control [the] narrative, and paint it as if the outbreak did not originate in China."
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [2] [3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]
According to a Ming Pao report published on 21 March 2022, of the 1,486 who died of COVID-19 after receiving at least one dose, 1,292 of them or 87%—had gotten the Sinovac vaccine. [203] The Centre for Health Protection's Chuang Shuk-kwan said that the Ming Pao report was inaccurate and has defended CorovaVac, saying "The issue is not about ...